Breg and Club Warehouse Launch Partnership in Australia

Breg, Inc. is a leading orthopedic bracing and billing services company.

Today they announced they have partnered with Australian-based distributor Club Warehouse to expand delivery of its premium, high-value orthopedic products in the Australian market.

Breg notes beginning February 15, 2021, they will offer its products to orthopedic practices and sports organizations across the continent, including the Australian Football League (AFL), National Rugby League (NRL) and Rugby Union Clubs.

“Club Warehouse not only has an impressive roster of customers that includes some of Australia’s most elite athletes – its team also shares our core values, centered on excellent customer service and enhanced patient care,” said Bianca Flikweert, Breg’s international director of sales.

Club Warehouse’s product portfolio extends from simple first aid needs to pharmacy, sports performance, and physiotherapy supplies, as well as sophisticated sports recovery equipment. To learn more about Breg’s full product portfolio, visit Breg.com.

“Breg’s bracing and cold therapy products are considered among the highest quality and highest value in our field,” said Club Warehouse Owner Ian Patrick. “We are thrilled to partner with Breg to expand availability to patients and providers across Australia.”

SourceBreg
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version